Treprostinil Palmitil

Small molecule

Treprostinil Palmitil is one of 81 small molecule programs targeting Interstitial Lung Disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial Lung DiseaseActive, not recruiting

Pulmonary Arterial HypertensionActive, not recruiting

Interstitial Lung DiseasePhase 2/Phase 3

Active, not recruiting

Pulmonary Arterial HypertensionPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

179 competitors in Pulmonary Arterial Hypertension

#DrugCompanyPhaseTrials

Gleevec

Novartis

Phase 3

6 2

Levitra

Bayer

Phase 3

1 3

Reata

Biogen

Phase 3

1 4

Aurlumyn

BBTG International Inc.

Phase 3

8 5

Flolan

Johnson & Johnson

Phase 3

1 6

Zesly

MMezzion Pharma Co. Ltd

Phase 3

1 7

Atrovent

Inhaled Iloprost

1 9

Rituxan

Roche

Phase 2

1 10

Nolvadex

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Pulmonary Arterial Hypertension

NCT05649748

Q4 2028

Phase 3Recruiting

Interstitial Lung Disease

NCT07179380

Q1 2029

Phase 3Not yet recruiting

Pulmonary Arterial Hypertension

NCT07481981

Q1 2031

Phase 3Not yet recruiting

Interstitial Lung Disease

NCT07234032

Clinical

Trials by Indication[1]

Pulmonary Arterial Hypertension5 trials

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Completed·IInsmed Incorporated·Phase 2·NCT05147805·102 enrolled

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

Terminated·IInsmed Incorporated·Phase 2·NCT04791514·1 enrolled

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

Not yet recruiting·IInsmed Incorporated·Phase 3·NCT07481981·344 enrolled

Show 2 more trials

An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Available·IInsmed Incorporated··NCT06939647

An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Active, not recruiting·IInsmed Incorporated·Preclinical·NCT05649748·91 enrolled

Interstitial Lung Disease4 trials

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Recruiting·IInsmed Incorporated·Phase 3·NCT07179380·344 enrolled

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Active, not recruiting·IInsmed Incorporated·Phase 2/3·NCT05649722·31 enrolled

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Not yet recruiting·IInsmed Incorporated·Phase 3·NCT07234032·344 enrolled

Show 1 more trial

A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Completed·IInsmed Incorporated·Phase 2·NCT05176951·39 enrolled

Tics1 trial

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Completed·IInsmed Incorporated·Phase 1·NCT06091579·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Treprostinil Palmitil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Treprostinil Palmitil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Treprostinil Palmitil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Insmed Incorporated company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: IInsmed Incorporated

Treprostinil Palmitil

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Q1 2029

Q1 2031

Trials by Indication[1]

Pulmonary Arterial Hypertension5 trials

Interstitial Lung Disease4 trials

Tics1 trial

References

Drug Info

Quick Facts

Related News